This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia.

Official Title

14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.

Conditions

Fibromyalgia

Study Type

Interventional

Study Design

Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Further Details

Primary Outcome Measures:

  • patient daily pain diaries

Study Start

June 2006

Eligibility & Criteria

Ages Eligible for Study: 18 Years and above
Genders Eligible for Study: Both
Inclusion Criteria:
ACR criteria for fibromyalgia
A score of more or equal to 40 mm on the Pain Visual Analog Scale (VAS)

 

Total Enrolment

740

Contact Details

Australian Locations:

Warrawong, New South Wales, 2502, Australia; Recruiting
Maroochydore, Queensland, 4558, Australia; Recruiting
Clayton, Victoria, 3168, Australia; Recruiting
Fitzroy, Victoria, 3065, Australia; Recruiting

 For more information on this trial, contact Pfizer

All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.